WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca PLC Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

AZN past earnings growth

How has AZN's earnings growth performed historically?
Company
81.13%
Industry
0.14%
Market
61.16%
AZN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AZN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AZN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AZN past revenue growth

How has AZN's revenue growth performed historically?
Company
3.29%
Industry
4.62%
Market
16.96%
AZN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AZN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AZN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AZN earnings and revenue history

Current Revenue
$45.8B
Current Earnings
$6.0B
Current Profit Margin
13%
AZN's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

AZN Return on Equity

Current Company
15.9%
Current Industry
34.1%
Current Market
188%
AZN's Return on Equity (15.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when AZN announces earnings.

AZN Return on Assets

Current Company
6.1%
Current Industry
8.3%
AZN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AZN Return on Capital Employed

Current Company
12.07%
Current Industry
14.8%
AZN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AZN vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AZN$45.81B$13.91B$5.96B+15.71%+17.70%
NVS$49.92BN/A$15.25B+1.48%+6.77%
PFE$58.50B$7.29B$2.12B+7.46%-27.52%
AMGN$28.19B$14.80B$6.72B+3.49%-0.22%
ABBV$54.32B$16.62B$4.86B+10.65%-5.75%
View Top General Drug Manufacturer Stocks

Astrazeneca Earnings & Revenue FAQ

What were AZN's earnings last quarter?

On Invalid Date, Astrazeneca (NASDAQ: AZN) reported Q4 2023 earnings per share (EPS) of $0.31, up 5.17% year over year. Total Astrazeneca earnings for the quarter were $960.00 million. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.29.

If you're new to stock investing, here's how to buy Astrazeneca stock.

What was AZN's earnings growth in the past year?

As of Q2 2024, Astrazeneca's earnings has grown 81.13% year over year. This is 81 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 0.14%. Astrazeneca's earnings in the past year totalled $5.96 billion.

What was AZN's revenue last quarter?

On Invalid Date, Astrazeneca (NASDAQ: AZN) reported Q4 2023 revenue of $12.02 billion up 7.28% year over year. In the same quarter last year, Astrazeneca's revenue was $11.21 billion.

What was AZN's revenue growth in the past year?

As of Q2 2024, Astrazeneca's revenue has grown 3.29% year over year. This is 1.33 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 4.62%. Astrazeneca's revenue in the past year totalled $45.81 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.